Common Contracts
2 similar Warrant Agreement contracts by LianBio
LIAN ONCOLOGY FORM OF WARRANT TO PURCHASE ORDINARY SHARESWarrant Agreement • October 1st, 2021 • LianBio • Pharmaceutical preparations
THIS WARRANT IS TO CERTIFY THAT, QED Therapeutics, Inc. (the “Purchaser” and, together with its nominees, successors or assigns, including any subsequent holder of this Warrant to whom it has been legally transferred, the “Holder”) is entitled to purchase from Lian Oncology, an exempted company organized under the laws of the Cayman Islands (the “Company”), 33,333 ordinary shares, par value US$0.0001 per share (subject to adjustment in accordance with the terms hereof, the “Warrant Shares”), at US$0.0001 per share (subject to adjustment in accordance with the terms hereof, the “Exercise Price”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Exclusive License Agreement, entered into as of October 16, 2019, by and between the Purchaser and the Company (the “License Agreement”).
LIAN ONCOLOGY FORM OF WARRANT TO PURCHASE ORDINARY SHARESWarrant Agreement • August 9th, 2021 • LianBio • Pharmaceutical preparations
THIS WARRANT IS TO CERTIFY THAT, QED Therapeutics, Inc. (the “Purchaser” and, together with its nominees, successors or assigns, including any subsequent holder of this Warrant to whom it has been legally transferred, the “Holder”) is entitled to purchase from Lian Oncology, an exempted company organized under the laws of the Cayman Islands (the “Company”), 33,333 ordinary shares, par value US$0.0001 per share (subject to adjustment in accordance with the terms hereof, the “Warrant Shares”), at US$0.0001 per share (subject to adjustment in accordance with the terms hereof, the “Exercise Price”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Exclusive License Agreement, entered into as of October 16, 2019, by and between the Purchaser and the Company (the “License Agreement”).
